ClinicalTrials.gg
Active, not recruitingNCT06797739Nutri-DICAUpdated Jan 28, 2025

Effect of Nutritional Counseling and Mediterranean Diet on Patients with Diverticular Disease

An interventional study of Nutritional counselling and Diet in Diverticular Diseases, sponsored by Regione del Veneto - AULSS n. 7 Pedemontana. Active, not recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-01-28.

Sponsored by Regione del Veneto - AULSS n. 7 Pedemontana · Not applicable, Interventional, and Treatment

Phase
Not applicable
Study type
Interventional
Enrollment
80
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-12

Among 11 studies in Diverticular Diseases with a site in Italy — 2 open to participants now, 3 under way, none of them phase 3. Diverticular Diseases · Italy.

Started
2023
with 4 others
No phase
3 of 11
none open now
Registered
8th of 11
by date
Lead sponsor
1 of 11
Regione del Veneto - AULSS n. 7 Pedemontana

Among the 11 studies in Diverticular Diseases with a site in Italy, this one is one of 5 that started in 2023, is one of 3 with no phase, and was the 8th registered.

By phase

11 studies; the count open now beside each. This study's row is marked.

Observational4 · 2 open
No phasethis study3 · 0 open
Phase 32 · 0 open
Phase 42 · 0 open

By the year they started

First in 2005; this study’s year is marked. 5 started in 2023.

Size and results

Median enrollment 80 across the 7 interventional studies, 250 across the 4 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.

Was this useful?
Watch this landscapeDownload CSVWith an account: a weekly mail of what changed among 11 studies in Diverticular Diseases with a site in Italy, or all of them as a file.
02

Study summary

Diverticular Disease (DD) is a frequent condition in Western populations and may be associated with complications including bleeding, perforation, acute diverticulitis, and colon strictures. Severity of diverticular disease and its association with prognosis in relation to surgery using the Diverticular Inflammation and Complication Assessment (DICA) classification has been validated in several studies. A sedentary lifestyle, poor fibre intake and other unhealthy dietary habits have been associated with DD. On the contrary, the Mediterranean Diet (MD), which involves factors such as consuming locally grown food products, family meals, conviviality, involvement in the preparation of meals, as well as high intake of vegetables, legumes, fruit and cereals, medium intake of fish, low intake of meat and saturated fat, high intake of unsaturated fat (particularly olive oil), a medium-low intake of dairy products (yogurt and cheese), and a moderate intake of wine, seems to protect against DD. Moreover, populations that follow the MD pattern show a 50% lower rate of cardiovascular mortality due to cardiovascular disease and show highest longevity. A common finding in clinical practice is that a majority of patients undergoing a new diet stop to correctly follow the diet in the long term, suggesting the importance of periodic counselling for patients.

The aim of the study is to evaluate the impact of MD on DD and on severity of DD, and to explore the impact of incorporating a dietitian-driven counselling program in this condition.

Read the detailed description

The investigators will verify whether a 12-week nutritional intervention is able to reduce DD-related symptoms, improve patient's quality of life and reduce the need for medication. DD severity will be assessed using DICA, MD adherence will be assessed with Medi-Lite (Mediterranean Literature scoring system), symptoms will be assessed with a VAS (visual analogue scale) questionnaire and IBS-SSS (the irritable bowel syndrome severity scoring system), nutritional status will be evaluated using BIA (bioelectrical impedance analysis) and metabolic blood parameters.

03

Conditions studied

  • Diverticular Diseases

Browse trials for

Keywords

  • DICA endoscopic score
  • Medi-LITE score
  • Symptomatic Uncomplicated Diverticular Disease (SUDD)
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have given written to participate
  • Diagnosis of SUDD defined as the presence of symptoms (mainly abdominal pain, but also constipation, diarrhea and bloating) in patients with a previous diagnosis of diverticular disease at colonoscopy in the absence of any current complications (stenoses, abscesses, fistulas)
  • DICA assessment during a colonoscopy

Exclusion criteria

Exclusion Criteria:

  • Acute or complicated diverticulitis
  • Hospitalized patients
  • Patients with active oncological diseases.
  • Former partial or total colonic resection or other surgical procedures for DD
  • Short bowel syndrome or active perianal fistulas
  • Female patients who are pregnant or breastfeeding
  • Patients with known malabsorption diseases (e.g. celiac disease)
  • Any unstable or uncontrolled cardiovascular, pulmonary, hepatic, renal, gastrointestinal, genitourinary, hematological, coagulation, immunological, endocrine/metabolic, or other medical disorder that, in the opinion of the investigator, would confound the study results or compromise patient safety
  • Any surgical procedure requiring general anesthesia within 30 days prior to enrollment or is planning to undergo major surgery during the study period
  • Patients undergoing a specific diet (e.g. diet for diabetics)
  • Patients with known and well-established food allergies or intolerance to dietary elements of MD
  • Patients with recent diagnosis of or non-controlled lactose intolerance
  • Active participation in other interventional or drug research projects in the study period.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
80 participants (estimated)

Study arms

  • Experimental
    Dietary counselling on Mediterranean Diet

    Patients will be asked to follow the Mediterranean Diet and to participate to an educational program

    Other: Nutritional counselling · Other: Diet

  • Experimental
    Mediterranean Diet

    Patients will be asked to follow Mediterranean Diet only

    Other: Diet

  • No intervention
    Controls

    Patients maintain their current lifestyle and dietary habits.

Interventions

  • OtherNutritional counselling

    Patients will be asked to follow the Mediterranean Diet and to participate to an educational program.

  • OtherDiet

    Patients will be asked to follow Mediterranean Diet only

06

What researchers measure

Primary outcomes

  1. Remission of symptoms

    The percentage of patients that will achieve symptom-free remission of symptoms

    Time frame: 12 weeks

  2. Adherence to diet

    The effect of a counselling program on Medi-LITE score

    Time frame: 12 weeks

  3. DICA and diet

    The differences in response based on basal DICA (Diverticular Inflammation and Complication Assessment, value 1-3, with DICA 3 meaning a worse outcome).

    Time frame: 12 weeks

Secondary outcomes

  1. Inflammation

    To determine the percentage of patients with a reduction of fecal calprotectin

    Time frame: 12 weeks

  2. Metabolism

    The percentage of patients with a modification in blood metabolic parameters: liver and renal function, cholesterol, HDL, LDL, triglycerides, glucose, HOMA (homeostasis model assessment) index, albumin.

    Time frame: 12 weeks

  3. Drug use

    The percentage of patients with modifications in drug therapy.

    Time frame: 12 weeks

07

Study locations

1 site
  • UOSD Endoscopia - Ospedale Alto Vicentino - AULSS 7 Pedemontana
    Santorso, Vicenza 36014, Italy
08

References and documents

Publications

  • Tursi A, Brandimarte G, Di Mario F, Lanas A, Scarpignato C, Bafutto M, Barbara G, Bassotti G, Binda GA, Biondi A, Biondo S, Cassieri C, Crucitti A, Dumitrascu DL, Elisei W, Escalante R, Herszenyi L, Kruis W, Kupcinskas J, Lahat A, Lecca PG, Maconi G, Malfertheiner P, Mazzari A, Mearin F, Milosavljevic T, Nardone G, Chavez De Oliveira E, Papa A, Papagrigoriadis S, Pera M, Persiani R, Picchio M, Regula J, Stimac D, Stollman N, Strate LL, Walker MM; DICA International Group. The DICA Endoscopic Classification for Diverticular Disease of the Colon Shows a Significant Interobserver Agreement among Community Endoscopists: an International Study. J Gastrointestin Liver Dis. 2019 Dec 19;28(suppl. 4):39-44. doi: 10.15403/jgld-558. PubMed 31930224 ↗
  • Tursi A, Brandimarte G, Di Mario F, Elisei W, Picchio M, Allegretta L, Annunziata ML, Bafutto M, Bassotti G, Bianco MA, Colucci R, Conigliaro R, Dumitrascu D, Escalante R, Ferrini L, Forti G, Franceschi M, Graziani MG, Lammert F, Latella G, Maconi G, Nardone G, Camara de Castro Oliveira L, Chaves Oliveira E, Papa A, Papagrigoriadis S, Pietrzak A, Pontone S, Poskus T, Pranzo G, Reichert MC, Rodino S, Regula J, Scaccianoce G, Scaldaferri F, Vassallo R, Zampaletta C, Zullo A, Piovani D, Bonovas S, Danese S; DICA International Group. Prognostic performance of the 'DICA' endoscopic classification and the 'CODA' score in predicting clinical outcomes of diverticular disease: an international, multicentre, prospective cohort study. Gut. 2022 Jul;71(7):1350-1358. doi: 10.1136/gutjnl-2021-325574. Epub 2021 Oct 26. PubMed 34702716 ↗
  • Sofi F, Dinu M, Pagliai G, Marcucci R, Casini A. Validation of a literature-based adherence score to Mediterranean diet: the MEDI-LITE score. Int J Food Sci Nutr. 2017 Sep;68(6):757-762. doi: 10.1080/09637486.2017.1287884. Epub 2017 Feb 9. PubMed 28276908 ↗

Individual participant data

Plan to share: No — Individual participant data must be submitted to local Ethical Committee

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Dec 2024, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2023
First posted
Jan 28, 2025
StartActual
Apr 4, 2023
Primary completionActual
Dec 16, 2024
CompletionEst.
Apr 4, 2025
Last update
Jan 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06797739
Lead sponsor
Regione del Veneto - AULSS n. 7 Pedemontana
Responsible party
Sponsor
First posted
Jan 28, 2025
Start date
Apr 4, 2023
Primary completion
Dec 16, 2024
Completion
Apr 4, 2025 (estimated)
Last update
Jan 28, 2025

Study contacts

Antonio Ferronato, MD
principal investigator · UOSD Endoscopia - Ospedale Alto Vicentino - AULSS 7 Pedemontana

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jan 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion